Gabapentinoids for chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis
T. Chang, Fuyu Yang, Yu‐Chang Liu, Cheng‐Hsien Hung
Abstract
Introduction Chemotherapy-induced peripheral neuropathy (CIPN) affects patients’ quality of life and treatment effectiveness. Gabapentinoids, like gabapentin and pregabalin, are often used for CIPN treatment, but their efficacy and safety remain uncertain. This study reviews and analyses randomised controlled trial data on this topic. Materials/methods We searched PubMed, Embase and Cochrane CENTRAL until 29 August 2022 for studies on gabapentinoid use in CIPN. Meta-analysis was performed using RevMan V.5.4 and the Metafor package in R. Outcomes included pain scores, quality of life and adverse drug events. Results For the prevention setting, our meta-analysis shows that pregabalin did not significantly improve average pain (standardised mean difference (SMD) −0.14, 95% CI −0.51 to 0.23; I 2 =26% (95% CI 0% to >98%)) or quality of life (mean difference (MD) 2.5, 95% CI −4.67 to 9.67; p=0.49) in preventing CIPN compared with placebo. However, it showed a potential trend towards reducing the worst pain (SMD −0.28, 95% CI −0.57 to 0.01; I 2 =0% (95% CI 0% to 98%; p=0.06)). For the treatment setting, some studies have shown a potential therapeutic effect of gabapentinoids. However, the results are not consistent between studies. Given the studies’ heterogeneity, a meta-analysis in treatment setting was not performed. Conclusion There is limited evidence to support the use of gabapentinoids in CIPN. In prevention setting, gabapentinoids do not significantly prevent CIPN. In treatment setting, studies have been inconsistent in their conclusions, lacking definitive benefits over placebo. More comprehensive and higher quality research is needed in the future. PROSPERO registration number CRD42022361193.